| |
| |
A Deloitte expert will be taking us thru a quick tour of the current pharmaceutical landscape and how it got that way followed by the looking glass of futures by the MD of one of India’s most revered MNC companies , Novartis India.
Speakers from India will cover BOTH SIDES of the recent concerns from the Indian government regarding FDI (Foreign Direct Investment). There is significant pressure to reduce FDI and dis-allow the direct foreign investment route. Will doing so truly contain drug pricess from rising for the Indian pharmaceutical sector? What happens to global investments pouring into India these days when FDI is curbed ?
US and Europe experts will address mergers and acquisitions track record when a global MNCs acquires an Indian pharma , discuss the various challenges with East-West alliances, and why sometime India to India mergers make better sense than one with a Western pharma.
For the future, pharmaceutical companies will continue to pursue acquisitions of innovative biotech products and companies, but are now carefully taking steps to leave in place the culture of these companies to protect the innovation they covet. In many cases instances, Big Pharma is seeking to emulate biotechs through partnerships or acquisitions.
|
| |
| |
|
|
|
